Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Antiviral Res. 2021 Mar 13;189:105062. doi: 10.1016/j.antiviral.2021.105062

Table 3.

Analysis of the effect of the drugs combination on HCMV replication.

Drug
Combination
(EC50a Ratiob)		 CI values extrapolated at the indicated
% of virus inhibition (mean ± SD)c
 CIwtd

 Drug
combination
effecte
50 75 90 95
ICZ + GCV (3.5:1) 0.635 ± 0.018 0.386 ± 0.039 0.243 ± 0.042 0.180 ± 0.039 0.258 Strong Synergism
ICZ + FOS (1:4) 0.593 ± 0.021 0.422 ± 0.029 0.306 ± 0.012 0.284 ± 0.035 0.335 Synergism
ICZ + LMV (3500:1) 0.750 ± 0.031 0.624 ± 0.022 0.522 ± 0.037 0.464 ± 0.019 0.542 Synergism
a

EC50 values for HCMV strain AD169 considered for each drug (approximating values obtained in PRA and reported in Table 1).

b

EC50 of drug1/EC50 of drug2 yielding an equipotent concentration ratio between the two combined drugs.

c

Combination index (CI) at the indicated % of virus inhibition values extrapolated by analysis with CalcuSyn Software. CI values represent the mean ± SD of n = 3 independent experiments in triplicate of duplicate.

d

Weighted average CI. Values were calculated as CIwt = (CI50 + 2 x CI75 + 3 x CI90 + 4 x CI95)/10.

e

Drug combination effect defined as: strong synergism for 0.1 <CIwt < 0.3 and synergism for 0.3<CIwt < 0.7, according to (Chou, 2006).